Embolization Particle Market Size, Share, Growth, and Industry Analysis, By Type (Microspheres, Particles (e.g. PVA Particles, Gelfoam Particles), Drug-eluting Beads (DEBs) and Radio-Embolic Microspheres (e.g. Therasphere and SIRSphere)), By Application (Uterine Fibroid Embolization, Prostatic Artery Embolization (treatment for Benign Prostatic Hyperplasia or BPH), Liver Tumor Embolization, Trauma Embolization and Others) and Regional Forecast to 2033

EMBOLIZATION PARTICLE MARKET REPORT OVERVIEW

The global Embolization Particle Market size was USD 2667.17 million in 2024 and is projected to touch USD 9021.75 million by 2033, exhibiting a CAGR of 14.5% during the forecast period.

Embolization particles serve as medical devices intended for blocking blood flow to designated areas of the human body for treating tumors and arteriovenous malformations and fibroids.

• 

  Request a Free Sample to learn more about this report

COVID-19 IMPACT

Embolization Particle Industry Had a Negative Effect Due to Delayed Elective Procedures and Reduced Patient Volume during COVID-19 Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The vast pressure on healthcare providers during the pandemic caused numerous elective medical operations with embolization therapy among them to be either suspended or canceled while COVID-19 cases gained priority status. Healthcare facilities directed their attention to COVID-19 patient care resulting in fewer individuals who underwent embolization procedures.

LATEST TRENDS

"Development of Targeted and Customized Embolization Particles to Propel Market Growth"

The medical field develops embolization particles which become customized to treat patients through the use of their unique tumor or vascular characteristics. Customized embolic procedures serve to improve treatment outcomes by decreasing side effects and raising overall performance. The growing demand for the embolization market relies on microspheres because they provide localized therapeutic methods. Patients can simultaneously benefit from tumor treatment through direct drug application in addition to embolization through the use of microspheres containing chemotherapeutic drugs or radioactive isotopes for transarterial chemoembolization (TACE) liver cancer therapy.

• 

  Request a Free Sample to learn more about this report

EMBOLIZATION PARTICLE MARKET SEGMENTATION

By Type

Based on type the market can be categorized into Microspheres, Particles (e.g. PVA Particles, Gelfoam Particles), Drug-eluting Beads (DEBs) and Radio-Embolic Microspheres (e.g. Therasphere and SIRSphere).

• Microspheres- Spherical microspheres serve as the main particles used for embolization procedures. The procedure uses spherical particles with different scale options which medicine employs for cancer management because these objects enable controlled therapeutic interventions while supplying medication transport mechanisms.

• Particles (e.g. PVA Particles, Gelfoam Particles)- Particle coils represent the main embolization therapy applied for multiple clinical procedures. These medical devices effectively close blood vessels through a mechanism that prevents blood access in particular tissue regions.

• Drug-eluting Beads (DEBs)- The design of Drug-eluting beads (DEBs) includes chemotherapy drug coatings which enables targeted delivery to tumor areas. The treatment enters the target area from the beads as they release the drugs over time which helps to minimize side effects.

• Radio-Embolic Microspheres (e.g. Therasphere and SIRSphere)- Radioembolic microspheres make up small spherical particles containing radioactive isotopes which clinicians use to treat liver cancer by radioembolization.

By Application

Based on application the market can be categorized into Uterine Fibroid Embolization, Prostatic Artery Embolization (treatment for Benign Prostatic Hyperplasia or BPH), Liver Tumor Embolization, Trauma Embolization and Others.

• Uterine Fibroid Embolization- Uterine fibroid embolization (UFE) functions as a minimally invasive method that stops the circulation of blood to uterine fibroids for treatment purposes.

• Prostatic Artery Embolization (treatment for Benign Prostatic Hyperplasia or BPH)- Benign Prostatic Hyperplasia (BPH) patients benefit from Prostatic artery embolization (PAE) as a minimally invasive BPH treatment when their prostate gland enlarges and produces urinary symptoms which include frequent urination and difficulty in urination together with urgency.

• Liver Tumor Embolization- TACE serves as one of the primary procedures to treat liver tumors with its main role in primary liver cancer (hepatocellular carcinoma) and metastatic tumors.

• Trauma Embolization- Medical teams use trauma embolization as an emergency procedure to stop bleeding that puts patients at risk of death particularly during situations where surgical intervention is not immediately possible or accessible.

Driving Factors

"Rising Prevalence of Cancer and Tumors to Drive Market Advancement"

One of the key driving factors in the Embolization Particle market growth is Rising Prevalence of Cancer and Tumors. The embolization particle market experiences growth due to the rising numbers of liver cancer alongside renal cancer and uterine fibroids cases. Both TACE and radioembolization treatment procedures encompass the utilization of embolization particles in their delivery of cancer therapies to various cancer types. Non-invasive treatments with abbreviated recovery intervals are gaining more public acceptance hence embolization emerges as a preferred medical choice resulting in rising use of embolization particles in cancer care.

"Increasing Preference for Minimally Invasive Procedures to Expand the Market"

Medical practices moving toward noninvasive procedures constitutes the primary driver of market growth for embolization particles. The approach features smaller incisions and causes reduced pain and delivers quicker healing as well as diminished medical complications than conventional surgical methods. Embolization continues to gain popularity because it delivers targeted treatment while shortening recovery periods so healthcare providers and patients choose it often. The market experiences growth because of mounting patient and healthcare provider preference for embolization.

Restraining Factors

"High Cost of Treatment Potential Impediments to Market Growth"

The cost of embolization procedures becomes high when healthcare providers use complicated embolization particles like drug-eluting or microspheres. The overall expense includes both the particle price alongside the medical procedures with imaging tests and expert healthcare services costs. Embolization treatments face availability challenges because of their high expense which restricts patients' healthcare access primarily in regions with limited healthcare funding such as low- and middle-income settings. The limited use of embolization procedures occurs because such treatments remain out of reach in these regions.

 Opportunity

"Rising Prevalence of Chronic Diseases To Create Opportunity for the Product in the Market"

The increasing number of cancer diagnoses in the population mostly affects liver cancer and lung cancer and solid tumors thus driving high demand for transarterial chemoembolization (TACE) treatments. The medical field is starting to adopt embolization particles as an alternative and less complex approach for treating untreatable tumors.

Challenge

"Lack of Skilled Professionals Could Be a Potential Challenge for Consumers"

The medical procedures of embolization require physician specialists who both posses extensive training in interventional radiology and catheter-based therapeutic techniques. The implementation of embolization procedures suffers due to insufficient professionals who have the required experience in certain areas. The procedure depends on state-of-the-art imaging methods (CT scans, MRI and fluoroscopy) to position the catheter along with embolization particles properly.

• 

  Request a Free Sample to learn more about this report

EMBOLIZATION PARTICLE MARKET REGIONAL INSIGHTS

• North America

North America has emerged as the most dominant region in the Embolization Particle market share due to a convergence of factors that propel its leadership in this dynamic industry. The healthcare delivery system in Europe maintains strong foundations yet receptive conditions for reimbursing embolization treatments remain less favorable when compared to North America.

• Europe

Europe has a robust healthcare system, but the adoption rate and reimbursement landscape for embolization procedures are generally not as favorable as in North America.

• Asia

The Asia Pacific market demonstrates strong expansion because its healthcare system continues to develop and patients are becoming more aware of chronic conditions. The healthcare system in this region displays lower overall market participation and medical capabilities than those found in North America.

KEY INDUSTRY PLAYERS

"Key Players Transforming the Embolization Particle Landscape through Innovation and Global Strategy"

Key enterprise players are shaping the Embolization Particle marketplace through strategic innovation and marketplace growth. The medical field sees substantial financial investment behind the research of improved embolic agents including drug-eluting microspheres alongside biodegradable embolic materials that provide enhanced therapeutic outcomes with lower adverse effects. The new sophisticated embolic agents outperform conventional medical embolization matter while delivering better clinical results to healthcare patients.

List Of Market Players Profiled

• BTG Medical (U.K.)
• Cook Medical (U.S.)
• Merit Medical (U.S.)
• Boston Scientific Corporation (U.S.)
• Sirtex Medical (U.S.)

INDUSTRIAL DEVELOPMENT

May 2023: The acquisition involved Merit Medical Systems, Inc. paying $100 million through cash to acquire both the BioSentry® Biopsy Tract Sealant System and dialysis catheter devices from AngioDynamics, Inc. 

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated time frame. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.